MX2020014265A - Anticuerpo variante que se une a cd38. - Google Patents

Anticuerpo variante que se une a cd38.

Info

Publication number
MX2020014265A
MX2020014265A MX2020014265A MX2020014265A MX2020014265A MX 2020014265 A MX2020014265 A MX 2020014265A MX 2020014265 A MX2020014265 A MX 2020014265A MX 2020014265 A MX2020014265 A MX 2020014265A MX 2020014265 A MX2020014265 A MX 2020014265A
Authority
MX
Mexico
Prior art keywords
antibody
present disclosure
binds
disclosure provides
variant antibody
Prior art date
Application number
MX2020014265A
Other languages
English (en)
Inventor
Barbara A Swanson
Heyue Zhou
Jian Cao
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2020014265A publication Critical patent/MX2020014265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación proporciona un anticuerpo anti-CD38 de clase IgG que tiene una capacidad mejorada para prepararse con mayores rendimientos en comparación con el anticuerpo precursor que tiene la secuencia precursora de tipo silvestre. La presente divulgación proporciona una cadena ligera del anticuerpo mutada que reduce la heterogeneidad de escisión para producción mejorada de una población homogénea de cadenas ligeras de anticuerpo.
MX2020014265A 2018-06-20 2019-03-08 Anticuerpo variante que se une a cd38. MX2020014265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687695P 2018-06-20 2018-06-20
PCT/US2019/021417 WO2019245616A1 (en) 2018-06-20 2019-03-08 Variant antibody that binds cd38

Publications (1)

Publication Number Publication Date
MX2020014265A true MX2020014265A (es) 2021-05-27

Family

ID=68984328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014265A MX2020014265A (es) 2018-06-20 2019-03-08 Anticuerpo variante que se une a cd38.

Country Status (10)

Country Link
US (1) US20210130484A1 (es)
EP (1) EP3810655A4 (es)
JP (2) JP2021528067A (es)
KR (1) KR20210022684A (es)
CN (1) CN112313250A (es)
AU (1) AU2019288972A1 (es)
CA (1) CA3103114A1 (es)
MX (1) MX2020014265A (es)
SG (1) SG11202012133TA (es)
WO (1) WO2019245616A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体
AU2020396548A1 (en) 2019-12-05 2022-07-14 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-CD47 antibody in combination with a tumor targeting antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428444B (zh) * 2005-10-12 2014-03-01 Morphosys Ag 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定
AU2012212297B2 (en) * 2011-01-31 2016-03-17 Northwestern University Injectable thermoresponsive polyelectrolytes
WO2013138431A1 (en) * 2012-03-15 2013-09-19 The Penn State Research Foundation, The Pennsylvania State University Methods for predicting and treating necrotizing enterocolitis in neonates
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
EP3368561A1 (en) * 2015-10-30 2018-09-05 Medimmune Limited Prevention of n-terminal truncation in igg light chains
KR20200017519A (ko) * 2017-06-20 2020-02-18 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38 항체 약물 접합체
JP2021501587A (ja) * 2017-11-03 2021-01-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ３８指向性キメラ抗原受容体構築物
SG11202008568WA (en) * 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体

Also Published As

Publication number Publication date
KR20210022684A (ko) 2021-03-03
SG11202012133TA (en) 2021-01-28
CA3103114A1 (en) 2019-12-26
EP3810655A4 (en) 2022-03-16
JP2024036508A (ja) 2024-03-15
CN112313250A (zh) 2021-02-02
WO2019245616A9 (en) 2020-12-24
JP2021528067A (ja) 2021-10-21
WO2019245616A1 (en) 2019-12-26
EP3810655A1 (en) 2021-04-28
US20210130484A1 (en) 2021-05-06
AU2019288972A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
AR101844A1 (es) Anticuerpos y conjugados modificados genéticamente con cisteína
SV2016005266A (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoblástica aguda
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201792584A1 (ru) Моноклональное антитело к pd-1 и способ его получения
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX353278B (es) Raton con cadena ligera comun.
NZ728749A (en) Anti-pd-l1 antibodies
CR20170026A (es) Anticuerpos anti-tau humanizados
CL2019001352A1 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo.
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
WO2018128691A8 (en) NON-HUMAN ANIMALS HAVING MODERN LAMBDA IMMUNOGLOBULIN LIGHT CHAIN LOCUS
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
CY1118592T1 (el) Μεθοδοι για την αναστολη της δεσμευσης της ενδοσιαλινης σε προσδετες
MX2018015721A (es) Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
PE20190209A1 (es) Anticuerpos anti-factor bb del complemento y uso de estos
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
MX2020014265A (es) Anticuerpo variante que se une a cd38.
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
NZ729747A (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado